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Borst, 1998; Gramaglia et al., 1998; Saoulli et al., 1998;
Bachmann et al., 1999; Watts and DeBenedette, 1999).Summary
In vitro studies have suggested that an efficient T cell
response requires the combined use of several ligand-We have found that DR6, a member of the TNF receptor
receptor pairs, including several TNF/TNFR family mem-family, is highly expressed in resting T cells and down-
bers, such as CD40, CD27, CD30, 4-1BB, and OX-40.regulated in activated T cells. DR6-targeted mutant
These molecules have been shown to deliver a costimu-mice were generated and showed normal develop-
latory signal for T cell proliferation, cytokine production,ment. However, DR6/ CD4 T cells hyperproliferated
and Th1/Th2 differentiation when engaged by theirin response to TCR-mediated stimulation and protein
corresponding ligands or specific agonist antibodiesantigen challenge. Activated DR6/ CD4 T cells ex-
(Gravestein and Borst, 1998; Grewal and Flavell, 1998;hibited upregulated CD25 expression and enhanced
Chen et al., 1999; Flavell, 1999; Watts and DeBenedette,proliferation in response to exogenous IL-2 stimula-
1999). Observations from these studies suggest thattion. In addition, increased CD28 and reduced CTLA-4
TNF/TNFR family members can act as important acces-expression were observed in these cells. Enhanced
sory molecules for promoting an optimal T cell immuneTh2 cytokine production by activated DR6/ CD4 T
response when combined with TCR signals.cells was associated with the increased transcription
While many molecules including TNF/TNFR familyfactor NF-ATc in nuclei. DR6, therefore, functions as
members may be important for positive regulation of Ta regulatory receptor for mediating CD4 T cell activa-
cell immune responses, some negative regulatory mole-tion and maintaining proper immune responses.
cules are also required to balance these responses. For
instance, CTLA-4, which is expressed on activated TIntroduction
cells and also binds to CD80 and CD86, is believed to
deliver a negative signal to the T cells. CTLA-4-deficientTumor necrosis factor (TNF) is a key mediator involved
mice develop a lymphoproliferative syndrome and auto-in immune regulation and inflammation. TNF family
immune disease (Khattri et al., 1999; Fraser et al., 1999;members mediate their biological functions through
Nakaseko et al., 1999). These negative signals are be-structurally related but functionally distinct receptors
lieved to be essential for regulating homeostasis of im-that belong to the TNF receptor (TNFR) family. The inter-
mune responses.actions between TNF family ligands and their receptors
Several transcription factors are required to promoteare involved in modulating a number of signaling path-
T cells to be fully activated to proliferate and differentiateways in the immune system, such as cell proliferation,
into effector cells. One of the most critical transcriptiondifferentiation, apoptosis, and survival (Wallach et al.,
factors is nuclear factor of activated T cells (NF-ATc).1999). While much attention has been focused on identi-
NF-ATc translocates to the nucleus in response to intra-fying the factors that are involved in regulating T cell
cellular calcium signaling following T cell activation andactivation and differentiation, the signaling molecules
thereby plays a key role to enhance TCR-mediated Tin this process have yet to be completely determined.
cell growth and differentiation (Kuo and Leiden, 1999;Interaction between the T cell receptor (TCR) and spe-
Kiani et al., 2000). NF-ATc-deficient T cells exhibited acific MHC-peptide complex on antigen-presenting cells
defect in peripheral T cell proliferation and Th2 differenti-(APC) is required for T cell activation. Additionally, a
ation (Ranger et al., 1998a; Yoshida et al., 1998). There-costimulatory signal is provided by ligation of corecep-
fore, regulating the transcriptional activity of NF-AT fam-tors on T cells with accessory molecules on APC
ily members is a key step in controlling T cell functions,(Lenschow et al., 1996b; Fallarino et al., 1998). The com-
especially effector functions.bination of these two signals induces optimal T cell
DR6 was identified as a death domain-containing re-activation.
ceptor within the TNFR superfamily (Pan et al., 1998).Among these costimulatory molecules, ligation be-
The extracellular cysteine-rich motifs of DR6 have abouttween CD28 on T cells and B7-1 (CD80) and/or B7-2
40% homology with osteoprotegerin (OPG) and TNFR2.(CD86) on APC has been well characterized as a critical
The expression of human DR6 was observed in a number
of tissues, including lymphoid tissues (Pan et al., 1998).1 Correspondence: yang_derek_di@lilly.com (D.D.Y.), hys@lilly.com
However, the physiological functions of DR6 remain un-(H.Y.S.), na_songqing@lilly.com (S.N.)
known. In the present study, we have generated DR6-2 Present address: Pharmacopeia, Inc., Princeton, New Jersey
08512. deficient mice by gene targeting. Our findings demon-
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Figure 1. Generation of DR6-Deficient Mice by Gene Targeting
(A) Northern blot analysis of DR6 transcripts in adult mouse tissues. The blot was also probed with a labeled -actin gene to ensure that each
lane has the same amount of RNA and that the RNA was intact (data not shown).
(B) Strategy for the targeted disruption of the DR6 gene. The pGT-N29-tk vector, the targeting vector pKO-DR6, the genomic region at the
DR6 locus, and the predicted structure of the mutated DR6 gene are illustrated. The restriction fragments used to construct the targeting
vector are indicated (1.2 kb StuI-XbaI fragment and 3.5 kb BamHI-EcoRV fragment). The coding regions of the exons are presented as striped.
Restriction enzyme sites (B, BamHI; N, NotI; Ns, NsiI; P, PstI; R, EcoRI; RV, EcoRV; Stu, StuI; Xba, XbaI) and the probe A for Southern blot
analysis are indicated.
(C) Germline transmission of the DR6 disruption is indicated by Southern analysis of mouse genomic DNA as the presence of all three expected
genotypes (/, /, and /). The upper band (4.7 kb) corresponds to the wild-type allele, and the lower band (3.1 kb) corresponds to
the mutant allele.
(D) Absence of the DR6 transcript in the DR6-deficient mice. Poly(A) RNA (0.5 g per lane) from kidneys of 5-week-old mice was analyzed
for DR6 transcripts with a 524 bp DR6 cDNA probe derived from exon 4 of full-length DR6 cDNA.
strate that DR6 is an important regulator for both T cell a targeting vector to replace exons II and III of the DR6
gene, including the translation initiation site, with a neo-activation and Th cell differentiation.
mycin resistance (pGK-neor) cassette (Figure 1B). Two
targeted mutant ES clones identified by Southern BlotResults
were injected into C57BL/6 blastocysts and resulted in
chimeric mice that transmitted the disrupted DR6 alleleGeneration of DR6-Deficient Mice
Like human DR6, murine DR6 is ubiquitously expressed through the germline. Heterozygotes were intercrossed
to generate homozygous mutant mice that were identi-in mouse tissues, and the highest expression was
observed in kidney and lymph node (Figure 1A). To de- fied by Southern blot analyses of genomic DNA. BamHI
bands, 3.1 and 4.7 kb, were detected as mutated andtermine the physiological functions of DR6 in vivo, we
generated DR6-deficient mice using homologous re- wild-type alleles, respectively (Figure 1C). The null muta-
tion of DR6 was demonstrated by the absence of DR6combination in embryonic stem (ES) cells. We designed
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Table 1. Immunofluorescent Profiles of T Cell Subpopulations
Thymus Spleen Lymph Node
T Cell Subpopulation WT (1.6  108)a DR6 KO (1.4  108) WT (1.2  108) DR6 KO (1.3  108) WT (5.9  107) DR6 KO (6  107)
CD4 (%) 9.4  0.3b 16.0  0.2 20  0.3 22.2  0.4 47.5  0.4 48.8  0.2
CD8 (%) 2.5  0.3 1.9  0.1 13.0  1 16.0  2 15.5  3 16.0  2
CD4 CD8 (%) 83.7  4 77.3  5 0.62  0.09 0.52  0.07 4.9  0.6 5.5  0.4
Data represent the mean  SEM of quadruplicate samples. There were four mice in each group.
a Total cell numbers.
b Percentage of individual cell population.
expression, as determined by Northern analysis of the presence of different concentrations of anti-CD3.
Again, T cells from DR6-deficient mice showed about amRNA isolated from kidneys of wild-type and homozy-
gous mutant mice (Figure 1D). Homozygous DR6-defi- 4-fold enhanced proliferation compared with control T
cells (Figure 2C).cient mice were born at the expected Mendelian ratio
and were fertile. Histological analysis revealed no signifi- To further examine if this enhanced T cell growth ap-
plies to the subpopulations of DR6-deficient T cells,cant changes in major organs, including lymphoid tis-
sues up to 6 months of age. The cellularity in spleen CD4 and CD8 T cell populations were purified and
cultured in 96-well plates coated with anti-CD3 and anti-and lymph nodes was comparable between wild-type
and DR6-deficient mice (Table 1). These results indicate CD28. As shown in Figure 3A, the absence of DR6 had
a profound hyperproliferative effect on the CD4 T cellsthat DR6 is not essential for normal mouse development
and lymphoid organogenesis. but not the CD8 subset. To determine if DR6 is directly
involved in TCR-mediated T cell growth, soluble DR6We further examined whether lymphoid cell lineage
development was affected in the absence of DR6. T was added to the wild-type T cell proliferation assay.
Hyperproliferation of wild-type T cells as well as CD4cells, B cells, monocytes, neutrophils, and natural killer
cells from thymi, lymph nodes, and spleens were ana- T cells was observed in a soluble DR6 concentration-
dependent manner compared with the control IgG1-lyzed by flow cytometry analysis (Table 1 and data not
shown). No significant differences in cell numbers of treated group (Figures 3B and 3C). These data suggest
that DR6 is an important factor in regulating TCR-medi-different subpopulations in immune system were ob-
served. The ratio between T and B cell populations, the ated T cell proliferation. To test if DR6 expression is also
affected through a TCR-mediated pathway, we analyzedpercentages of CD4 and CD8 populations, as well as
the activation stage of B and T cell populations also DR6 expression in resting versus activated CD4 T cells.
Cells were harvested at 0, 24, and 48 hr after incubationappeared to be normal (data not shown), suggesting
that the absence of DR6 had no effect on cell lineage with anti-CD3 and anti-CD28, and the expression of DR6
was determined by real-time PCR. Resting CD4 T cellsdevelopment in the immune system.
expressed the highest level of DR6. However, after 48
hr activation, expression of DR6 was significantly re-CD4 T Cell Proliferation Is Enhanced in DR6-Deficient
duced in CD4T cells (Figure 3D). These data are consis-Mice upon TCR Stimulation In Vitro
tent with the effects of DR6 deficiency observed in vitro.Since several TNF/TNFR family members were demon-
Increased T cell proliferation after stimulation couldstrated to deliver a costimulatory signal for T cell im-
be due to either increased cell growth or reduction ofmune response, we decided to examine if disruption of
cell death after disruption of DR6. Therefore, we nextDR6 affected T cell functions in vitro. Purified T cells
performed an activation-induced cell death (AICD)from spleens were cultured in microtiter plates coated
assay. No difference was observed between wild-typewith different suboptimal doses of anti-CD3 and anti-
and DR6-deficient T cells in this assay (Figure 3E). TheseCD28 antibodies, and T cell proliferation was deter-
data suggested that the increased growth of DR6-defi-mined by the [3H]thymidine incorporation after a 48 hr
cient CD4 T cells was due to enhancement of T cellincubation. Interestingly, the proliferation of T cells from
proliferative response after in vitro stimulation, whichDR6-deficient mice was enhanced 2- to 4-fold in re-
was supported by markedly increased BrdU labeling insponse to anti-TCR/anti-CD28 compared with wild-type
DR6-deficient T cells in vitro (data not shown). TheseT cells (Figure 2A). The level of IL-2 secreted in these
results were consistent with our observation that theprimary cultures also was examined after 24 hr incuba-
number of T cells remained at similar level in naive wild-tion and showed no significant differences (Figure 2B).
type and DR6-deficient mice and support the hypothesisThese results suggest that DR6 might negatively regu-
that DR6 serves as a negative regulator for CD4 T celllate T cell receptor-mediated cell growth, and the en-
growth after TCR stimulation.hanced DR6-deficient T cell proliferation was not due
to the higher IL-2 production.
To determine if enhanced T cell growth is CD28 de- Increased Th2 Cytokine Production
in DR6-Deficient Micependent, we further analyzed the proliferative response
of DR6-deficient T cells in the absence of CD28 signal. When activated by APCs, naive CD4 T cells undergo
clonal proliferation and produce IL-2. The activatedPurified T cells isolated from spleens of DR6-deficient
mice and wild-type littermates were stimulated only in CD4 T cells may then become Th1 or Th2 effector cells,
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higher levels of Th2 cytokines, including IL4, IL-5, IL-10,
and IL-13, while the secretion of Th1 cytokines, such
as IL-2 and IFN-, remained comparable to the control
CD4T cells (Figure 4A). These data demonstrated that
disruption of DR6 resulted in a cytokine production pro-
file characteristic of Th2 cells.
To exclude the possibility that the increased secretion
of Th2 cytokines was due to the enhanced T cell prolifer-
ation, the cells were stimulated with anti-CD3/anti-CD28
for 48 hr, washed, counted, and then seeded at the
same number for another 12 hr stimulation. Under these
conditions, significantly higher Th2 cytokine secretion
was observed in DR6-deficient T cells, whereas Th1
cytokine secretion remained at a similar level (Figure
4B). This result indicates that enhanced secretion of Th2
cytokines from DR6-deficient T cells was not due to
expansion of the cells. To confirm this, we examined the
Th differentiation of wild-type and DR6-deficient CD4 T
cells in vitro. Purified CD4 T cells from DR6-deficient
mice stimulated under Th2 condition showed dramati-
cally increased IL-4 production compared to wild-type
CD4 T cells (Figure 4C). In contrast, under Th1 differen-
tiation condition, there were no obvious differences in
the production of the Th1 cytokine IFN- between wild-
type and DR6-deficient mice. Strikingly, DR6-deficient
CD4 T cells produced 300-fold higher IL-4 compared
with wild-type T cells, even under Th1 condition (Figure
4C). These data demonstrate that absence of DR6 during
an ongoing immune response stimulates the establish-
ment of a Th2 response.
T Cell Priming and Cytokine Production Are
Enhanced in DR6-Deficient Mice
To define the in vivo effects of DR6 deficiency on anti-
gen-specific T cell activation and proliferation, DR6-
deficient mice and their wild-type littermates were im-
munized with the protein antigen keyhole limpet hemo-
cyanin (KLH). CD4 T cells were then purified from
Figure 2. Enhanced Proliferation of Peripheral DR6-Deficient T Cells draining lymph nodes, and in vitro T cell proliferative recall
in Response to Anti-TCR/Anti-CD28 or Anti-TCR Stimulation responses were examined in the presence of APCs and
(A) Purified T cells from spleen were cultured for 48 hr in a 96-well KLH. As shown in Figure 5A, significantly enhanced T
plate coated with different concentrations of anti-CD3 and anti- cell proliferative response was observed with DR6-defi-
CD28. [3H]thymidine was added to the culture for the last 12 hr of cient CD4 T cells. At a concentration of 100 g/ml of
incubation. The amount of [3H]thymidine incorporation was exam-
KLH, the T cell proliferative response was 35-fold higherined and used to determine the proliferation of peripheral T cells in
than the control T cells (Figure 5A). Similarly enhancedresponse to cross-linking TCR and CD28. (B) IL-2 secretion from
responses were observed with another protein antigen,the purified T cells was examined by ELISA after 24 hr stimulation
with anti-CD3/anti-CD28. (C) Purified T cells from spleen were stimu- hen egg lysozyme (HEL) (Figure 5B). However, it was not
lated with anti-CD3 for 48 hr. [3H]thymidine incorporation was used clear from these data whether the enhanced proliferative
to estimate T cell responses after stimulation. The above data repre- responses in DR6-deficient mice occurred at the level
sent five independent experiments. DR6-deficient T cells were la-
of the APC, the CD4 T cell, or both. To address thisbeled as DR6 KO for this figure and the rest of figures in this paper.
issue, KLH-primed CD4 T cells purified from wild-type
and DR6-deficient mice were examined for their recall
response in the presence of wild-type or DR6-deficientwhich mediate inflammatory or humoral responses, re-
spectively. Although the polarization of Th cell differenti- APC. The T cell recall response for DR6-deficient CD4
T cells remained at a similar level in the presence ofation is, at least in part, determined by the cytokine
environment, signals from the TCR-CD3 complex and wild-type APC (data not shown), indicating that DR6 is
important to balance antigen-specific T cell responsesfrom the costimulatory factor CD28 may also affect cyto-
kine production by mechanisms not yet understood during both the priming and effector phases of T cell
activation. In addition, we also measured cytokine pro-(Constant and Bottomly, 1997). To investigate if DR6 has
effects on Th cell differentiation, we measured cytokine duction from the primed T cell culture. The production
levels of the Th1 cytokine (IFN-) and Th2 cytokines (IL-4,production by purified CD4 T cells after stimulation with
anti-CD3 and anti-CD28. Compared with wild-type T IL-5, IL-10) were significantly higher in DR6-deficient
CD4 T cells compared to those of wild-type CD4 Tcells, DR6-deficient CD4 T cells secreted about 5-fold
Regulatory Role of DR6 in T Cell Immune Responses
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Figure 3. Enhanced Proliferation of DR6-Deficient CD4 T Cells
(A) CD4 and CD8 T cells were purified as described in the Experimental Procedures. The purified subpopulations of T cells were cultured
for 48 hr with plate-bound anti-CD3 and anti-CD28. Proliferation was determined after 48 hr by [3H]thymidine incorporation. (B) Soluble DR6
and IgG1 were used to treat wild-type T cells to block the interaction between the putative DR6 ligand and DR6 in the presence of anti-CD3.
The cells were treated for 48 hr and subsequently pulsed with [3H]thymidine. (C) Soluble DR6 and IgG1 were used to treat wild-type CD4 T
cells to block the interaction between the putative DR6 ligand and DR6 in the presence of anti-CD3. The above data represents five independent
experiments. (D) Real-time PCR to determine the expression level of DR6 in CD4 T cells before and after stimulation with 1 g/ml anti-CD3/
anti-CD28 at different time points. (E) The T cells from wild-type and DR6-deficient mice were treated as described, and the percentage of
cells undergoing apoptosis was determined by staining with Annexin V and measurement by flow cytometry. Three other independent
experiments showed similar results in this study.
cells (Figure 5C). The adjuvant we used in this study can DR6-deficient T cells, we examined the expression level
of CD25 on activated CD4 T cells. T cells from wild-strongly promote Th1 response, which may explain the
higher Th1 response of CD4 T cells from DR6-deficient type and DR6-deficient mice were activated with anti-
CD3 and anti-CD28 for 24 hr, and cell surface expressionmice. Together, these results suggest that DR6 is criti-
cally involved in regulating Th cell immune response in of CD25 was measured by flow cytometry analysis. Strik-
ingly, CD25 level was significantly higher in DR6-defi-vivo.
cient T cells (Figure 6A), suggesting that enhanced IL-2
signaling might account for the hyperproliferation ob-CD25 and CD28 Expression Is Upregulated
and CTLA-4 Is Downregulated in Activated served in DR6-deficient T cells. To confirm this hypothe-
sis, T cells were activated for 12 hr with anti-CD3 andDR6-Deficient T Cells
Signaling through the IL-2 receptor plays a pivotal role anti-CD28, washed, and stimulated with IL-2 for 48 hr.
T cell proliferation was measured by [3H]thymidine incor-for T cell growth. As shown in Figure 2B, secretion of
IL-2 was not increased in the absence of DR6. To deter- poration. As shown in Figure 6B, IL-2 stimulated a signifi-
cantly higher proliferative response in DR6-deficient Tmine if IL-2 receptor (CD25) expression was altered in
Immunity
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Figure 4. Increased Th2 Cytokine Production in DR6-Deficient Mice
(A) Purified CD4 T cells from WT and DR6-deficient mice were stimulated with plate-bound anti-CD3 plus anti-CD28 for 48 hr. The supernatant
was harvested to determine cytokine levels by ELISA. (B) Th1 and Th2 cytokine production from wild-type and DR6-deficient T cells after
normalization with cell numbers. (C) Purified CD4 T cells were differentiated under Th1 conditions and Th2 conditions as described, and the
cytokine secretions after differentiation were determined by ELISA. The data represent the results from three independent experiments.
cells compared with wild-type T cells, indicating that receptors after stimulation, the expression of CTLA-4
and CD28 were examined before and after TCR stimula-enhanced proliferation observed in activated DR6-defi-
cient T cells could be due to the higher expression level tion. No difference was observed before stimulation
(data not shown). Upon stimulation, the cell surface levelof CD25.
In addition to CD25, which is required for IL-2-medi- of CTLA-4 was clearly downregulated in DR6-deficient
T cells (Figure 6C). In contrast, CD28 expression wasated T cell growth, CD28 and CTLA-4 are also involved
in regulating T cell activation, proliferation, and TCR- upregulated and exhibited two times higher than wild-
type T cells in activated DR6-deficient T cells (Figuremediated immune responses (Fallarino et al., 1998; Fra-
ser et al., 1999). To determine if the absence of DR6 6D). Furthermore, the effect of DR6 deficiency on the
expression of these key molecules on activated T cellsaffects cell surface expression of these two important
Regulatory Role of DR6 in T Cell Immune Responses
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Figure 5. Enhanced In Vivo CD4 T Cell Priming, In Vitro T Cell Recall Responses, and Cytokine Production in the Absence of DR6
(A) CD4 T cells from DR6-deficient mice have enhanced recall proliferation in responses to protein antigens. Wild-type mice and DR6-
deficient mice were immunized with KLH in the hindfootpads. At 9 days after immunization, draining lymph nodes were extracted and subjected
to an in vitro challenge with various concentrations of KLH in the presence of antigen-presenting cells. After culturing for 4 days, [3H]thymidine
uptake was measured. (B) Wild-type and DR6-deficient mice were immunized with another protein antigen, HEL, and the CD4 T cell recall
responses were measured as above. (C) The supernatants from in vitro T cell recall responses of wild-type and DR6-deficient mice were
collected, and IL-4, IL-5, IL-10, and IFN- levels were measured by ELISA. The data represent the results from four mice in each group.
appears to be specific, since other activation markers, Absence of DR6 Results in Increased NF-ATc Nuclear
Translocation and DNA Binding Activitysuch as CD69, did not show significant differences be-
tween wild-type and DR6-deficient T cells (data not To further understand the potential mechanism through
which DR6 regulates T cell immune response, we nextshown). Together, the higher cell surface expression of
CD25, combined with the distinct surface expression examined the impact of DR6 deficiency on NF-ATc and
NF-B, which are key transcription factors involved inlevel of CTLA-4 and CD28, may contribute to the ob-
served increase in CD4 T cell proliferation and Th2 TCR-mediated signaling. Upon T cell activation, NF-ATc
is dephosphorylated and translocated into nucleus tocytokine production in activated DR6-deficient T cells
both in vivo and in vitro. activate gene transcription, whereas NF-B is translo-
Immunity
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Figure 6. Potential Mechanisms for Enhanced T Cell Growth and Upregulating Th2 Cytokine Production in the Absence of DR6
(A) Cell surface expression of CD25 from wild-type (left panel) and DR6-deficient CD4 T cells (right panel) after 24 hr stimulation with 0.5
g/ml anti-CD3 and anti-CD28.
(B) Enhanced T cell proliferation in response to exogenous IL-2. CD4 T cells were stimulated with anti-CD3 and anti-CD28 (0.5 g/ml) for
12 hr, and cells were washed and incubated with 50 ng/ml IL-2 for another 48 hr.
(C) The surface expression of CTLA-4 on wild-type (left panel) and DR6-deficient CD4 T cells (right panel) after 72 hr stimulation with anti-
CD3 (1 g/ml) was measured by flow cytometry.
(D) The surface expression of CD28 on wild-type (left panel) and DR6-deficient CD4 T cells (right panel) after 72 hr stimulation with anti-CD3
(1 g/ml) was measured by flow cytometry.
(E) The protein levels of NF-ATc and NF-kB p50 in the nuclear extracts were measured by immunoblot analysis. Nuclear extracts were made
from CD4 T cells before and after stimulation with anti-TCR/anti-CD28 (1 g/ml) for 72 hr. Nuclear extracts were prepared as described in
Experimental Procedures, and immunoblot analyses were performed with specific antibodies.
(F) Nuclear NF-ATc from activated wild-type and DR6-deficient CD4 T cells was functional as confirmed by gel mobility shift assay. The
middle bands were nonspecific binding, since they were not competed by cold homologous oligonucleotide.
cated into nucleus after disassociating from phosphory- tition and anti-NF-ATc supershift assays (data not
shown). In contrast, the NF-B pathway was not af-lated IB (Olsson et al., 1999). Purified CD4 T cells
from wild-type and DR6-deficient lymph nodes were fected, as demonstrated by the similar nuclear level of
p50 Rel A protein after stimulation in both wild-type andstimulated with anti-TCR, and nuclear extracts were
subsequently prepared and subjected to Western blot DR6-deficient CD4 T cells (Figure 6E). Nuclear level of
another member of the NFAT family, NF-ATp, was alsoanalyses. These studies showed that the level of NF-
ATc in the nucleus was dramatically increased in DR6- tested in our study, and no significant difference was
observed (data not shown). These data provided con-deficient T cells. The increased NF-ATc in the nucleus
of DR6-deficient T cells is not due to the enhanced NF- vincing evidence that DR6 can specifically mediate NF-
ATc activation and its DNA binding activity in nucleusATc in these cells, since no significant difference was
observed for total and cytoplasmic NF-ATc levels upon upon TCR stimulation.
stimulation (Figure 6E and data not shown). Conse-
quently, higher DNA binding activity of NF-ATc from Discussion
DR6-deficient T cells was observed in the gel mobility
shift assay (Figure 6F), and the specificity of DNA binding DR6 is a member of the TNF receptor family. A recent
study has suggested that it may be involved in mediatingwas confirmed by homologous oligonucleotide compe-
Regulatory Role of DR6 in T Cell Immune Responses
31
apoptosis and activation of NF-kB and JNK signaling downregulated in activated DR6-deficient T cells com-
pared with wild-type T cells. Furthermore, DR6-deficientin vitro (Pan et al., 1998). However, the physiological
functions of DR6 still remain unknown. To determine the T cells showed augmented cell proliferation and cell
cycle progression in response to exogenous IL-2 (Figurein vivo function of DR6, we generated DR6-deficient
mice by gene targeting and extensively investigated the 6B and data not shown). These results suggest that
enhanced T cell proliferation in response to plate-boundimpact of DR6 deficiency on modulating T cell immune
responses. Our results show that DR6 is not required antibodies is at least partially due to the increased ex-
pression of IL-2 receptor, whereas the increased CD28for normal development. However, deficiency of DR6
led to hyperproliferation of CD4 T cells in response to and reduced CTLA-4 expression could play an important
role when APCs deliver the T cell activating signals (e.g.,TCR stimulation and protein antigen challenges. En-
hanced Th2 cytokine production was also observed in in vivo foreign antigen challenge). Another possibility is
that CD4 T cell hyperproliferation could be the resultDR6-deficient mice. DR6 appears to mediate these ef-
fects by regulating key molecules involved in T cell acti- of reduction of activation-induced cell death, since DR6
is a death domain-containing receptor, and it was shownvation and differentiation upon stimulation of T cells.
Thus, DR6 functions as a critical molecule in regulating to be able to induce apoptosis in some cell types from
in vitro study (Pan et al., 1998). However, no differencethe TCR signaling pathway and plays an important role
in mediating T cell functions. in activation-induced cell death was observed between
wild-type and DR6-deficient T cells (Figure 3E). TheseRecently, interactions between TNF and TNF receptor
family members, including CD40/CD40L, CD30/CD30L, data indicate that DR6 may function as a regulatory
receptor rather than as an apoptosis modulator for TCR-CD27/CD27L, 4-1BB/4-1BBL, RANK/RANKL (OPGL),
HVEM/LIGHT, and OX40/OX40L, have also been demon- mediated signaling.
CD28 is one of the most critical costimulatory mole-strated in mediating T cell costimulation and/or antigen-
presenting cell activation (Reviewed by Watts and De- cules and plays an important role in stimulating T cell
proliferation and Th2 cell differentiation (Lenschow et al.,Benedette, 1999; Tamada et al., 2000). In this study,
we demonstrated that the absence of DR6 resulted in 1996a, 1996b; Khattri et al., 1999). In contrast, CTLA-4,
which is homologous to CD28, binds to the same ligandenhanced CD4 T cell growth in a CD28-independent
manner in vitro. Under in vitro conditions investigated, and delivers a negative signal to T cells that leads to
the inhibition of T cell proliferation (Fallarino et al., 1998;mature peripheral T cells from DR6-deficient mice dis-
played a significantly stronger CD4 T cell proliferative Oosterwegel et al., 1999). Furthermore, the CD4 T cell
subset present in CTLA-4-deficient mice showed pre-response than cells from wild-type littermates upon ac-
tivation with suboptimal concentrations of anti-TCR dominantly Th2 responses and secreted high levels of
IL-4 and IL-5 upon TCR stimulation. In contrast, CTLA-4or anti-TCR combined with anti-CD28 costimulation,
whereas CD8 T cell growth was unaffected. Interest- costimulation resulted in differentiation of naive CD4
T cells toward Th1 and inhibits Th2 subset differentiationingly, DR6 is expressed in both CD4 and CD8 T cells.
The highest expression of DR6 was observed in the by affecting IL-4 production (Oosterwegel et al., 1999;
Nariuchi and Kato, 2000). Therefore, reduction of CTLA-4resting CD4 and CD8 T cells. DR6 expression level
was dramatically reduced after 48 hr stimulation (Figure expression or increased CD28 expression should result
in increases in both T cell proliferation and Th2 differenti-3D and data not shown). Our in vitro study only showed
profound effect of DR6 deficiency on CD4 T cells. The ation, which was demonstrated in our DR6-deficient
mice. Previous studies have demonstrated that CTLA-4-explanation for this observation is not immediately ap-
parent and could be due to difference in TCR signaling deficient mice have a dramatic accumulation of T cells
in lymph nodes, and these T cells exhibited an activatedmechanism or difference of effector molecules coupled
to DR6 between these two subsets of T cells. For exam- phenotype (Madelbrot et al., 1999). However, no signifi-
cant difference was observed in the numbers of thymusple, the expression level of DR6 ligand, yet to be identi-
fied, on CD8 T cells in our in vitro study may be below and peripheral T cells in naive DR6-deficient mice. In
contrast, T cells from draining lymph nodes of DR6-the threshold that is required for delivering the inhibitory
effect of DR6 on T cell growth. deficient mice were about three times more abundant
than those of their wild-type littermates after KLH chal-CD4 T cells from DR6-deficient mice showed en-
hanced proliferation in response to protein antigens and lenge (data not shown), which is consistent with the
observation that CTLA-4 is downregulated only after TTCR stimulation. The higher proliferation could be due
to increased TCR signaling through increased T cell cells are activated (see Figure 6C). These data strengthen
the evidence that DR6 may modulate signals generatedreceptor expression. However, no difference of cell sur-
face expression of TCR/CD3 complex was observed through the TCR/CD28/CTLA-4 pathway.
Development and responses of immune system arebetween wild-type and DR6-deficient T cells before and
after stimulation (data not shown). Furthermore, combi- well coordinated by an interacting network of transcrip-
tion factors. One of the most important transcriptionnation of ionomycin and PMA also enhanced DR6-defi-
cient CD4 T cell proliferation (data not shown). This factors, NF-ATc, has been demonstrated to play a criti-
cal role in promoting peripheral T lymphocyte prolifera-suggests that the phenotypes observed in DR6-deficient
T cells might be due to its effect on either downstream tion and Th2 cell differentiation. NF-ATc is also neces-
sary for optimal IL-4 gene expression, which is essentialTCR signaling or through regulating other key molecules
on T cells involved in controlling T cell growth. In this for Th2 cell polarization (Yoshida et al., 1998; Ranger et
al., 1998a; Kuo and Leiden, 1999). We showed here thatstudy, we showed that both IL-2 receptor (CD25) and
costimulatory receptor (CD28) are more dramatically the nuclear level of NF-ATc was significantly increased
in activated DR6-deficient CD4 T cells, and the accu-upregulated and resulted in at least a 2-fold increase,
whereas inhibitory receptor (CTLA-4) is significantly mulated NF-ATc in DR6-deficient T cells was functional
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England BioLabs, Beverly, MA) by replacing an internal 3.4 kb XbaI-as shown by the enhanced DNA binding activity (Figure
BamHI fragment of DR6 (encompassing the translation initiation6F). Interestingly, NF-ATc is also involved in upregulat-
site) with a neomycin resistance cassette (pGK-neo). The neomycining CD25 expression in activated T cells (Schuh et al.,
resistance cassette was placed in the antisense orientation to DR6
1998), which is consistent with our observation. Further- transcription. A 2.0 kb MCl-tk cassette was added to the 5	 end of
more, nuclear level of NF-ATp, which is another member the Stu-EcoRV DR6 genomic fragment.
R1 ES cells were electroporated with Not-linearized pKO-DR6.of NFAT family to serve as a negative regulator for T
Genomic DNA from transfectants resistant to G418 (300 g/ml)cell proliferation and Th2 cell differentiation (Ranger et
(GIBCO-BRL, Rockville, MD) and gancyclovir (2M) were character-al., 1998b), exhibited no significant difference in our
ized by BamHI digestion and hybridization with probe A. This probestudy.
is a 200 bp BamHI-StuI fragment of the DR6 locus. Chimeric mice
NF-ATc and NF-ATp double-knockout T cells have were produced by microinjection of targeted mutant embryonic
been shown to be deficient in global cytokine production stem cells into 3.5-day-old C57BL/6 (B6) blastocysts. The contribu-
tion of embryonic stem cells to the germline of chimeric mice wasand T cell effector functions (Peng et al., 2001), further
assessed by breeding with B6 mice and screening for agouti off-supporting that NF-ATc and NF-ATp are essential for
spring. Germline transmission of the DR6 mutation to their F1 129/the completion of T cell differentiation. However, the
B6 offspring was confirmed by Southern analysis of tail DNA. F2functions of NF-ATc and NF-ATp in regulating the pro-
animals were maintained in sterilized microisolator cages and used
duction of effector cytokines may be largely redundant, for further analyses.
as shown by the previous work from NFAT single-mutant
T cells (Hodge et al., 1996; Ranger et al., 1998a). Thus, RNA Preparation and Northern Blot Analysis
Kidneys from wild-type and DR6-deficient mice were used for totalthe increased nuclear level of NF-ATc in the activated
RNA preparation with the TRIzol reagent protocol as recommendedDR6-deficient T cells makes a major contribution to the
by the manufacturer (GIBCO-BRL). Northern blot analysis was per-enhanced Th2 cytokine production, implicating that DR6
formed with poly(A) RNA from wild-type and DR6-deficient mouseplays a predominant role in Th cell differentiation. Our
kidneys. Poly(A)RNA was prepared from the total RNA, using Oligo-
data demonstrate that DR6 is an important regulatory tex (Qiagen, Santa Clarita, CA). The probe for the Northern blot was
factor involved in controlling TCR-mediated T cell differ- a PCR-amplified 524 bp fragment and corresponding to nucleotides
1340–1864 of the murine DR6 cDNA. The forward primer and reverseentiation through the NF-ATc pathway. NF-ATc has been
primer were 5	-GGTATTGACATCTTGAAGCTTGTAGCA-3	 and 5	-shown to be dephosphorylated by calcineurin in cytosol
GACCTGCCGCAACACTGTGTGTCC-3	, respectively. The probeand translocated into the nucleus upon TCR activation.
was labeled with [32P]d-CTP with Primer-it II labeling kit (StratageneThe translocated NF-ATc can then be phosphorylated
Inc.). Hybridization was performed according to the manufacturer
and exported out of the nucleus by GSK3 (Beals et (Clontech, Pola Alto, CA).
al., 1997). NF-ATc is believed to be involved in JNK
signaling, whereas JNK1/JNK2-deficient T cells showed Real-Time Quantitative PCR
The expression pattern of DR6 was determined by quantitative PCRhigher nuclear levels of NF-ATc and produce increased
analysis (Taqman, Applied Biosystems, Foster City, CA) usingTh2 cytokines (Dong et al., 1998, 2000; Chow et al.,
gene-specific oligonucleotides for DR6 (probe 5	-FAM-CCACGATG2000). Interestingly, overexpression of DR6 was shown
TCCCTTCCTCCACCTATG-TAMRA and primers 5	-TTCTCACCCTto activate JNK in vitro (Pan et al., 1998), and JNK was
GAGCATATGGAA and 5	-TGTTGAGTTCATGCCTTGGG) or 18s
demonstrated to inhibit targeting of the protein phos- rRNA (part 4310893E, Applied Biosystems). The PCR reactions in-
phatase calcineurin to NF-ATc (Chow et al., 2000). cluded cDNA made from T cells stimulated at different time points
and were performed in an ABI 7700 (Applied Biosystems) usingTherefore, absence of DR6 may, to some extent, reverse
standard conditions. The relative amount of either DR6 or 18s RNAthe inhibitory effect of JNK on calcineurin to NF-ATc
in each sample was calculated from a standard curve made from aand promote nuclear translocation of NF-ATc.
dilution series of one of the samples. The amount of DR6 RNA wasTogether, we provided convincing evidence that DR6
then normalized to the amount of 18s rRNA.
functions as a regulatory molecule in CD4 T cells for
TCR-mediated cell proliferation and differentiation, by Flow Cytometry Analysis
mediating nuclear levels of an important transcription Characterization of lymphocyte populations in wild-type and DR6-
deficient mice was determined by staining cells from bone marrow,factor, NF-ATc, and several critical molecules, such as
thymus, lymph nodes, and spleen with fluorescent antibodies toCD25, CD28, and CTLA-4, on activated T cells. Modula-
specific cell surface markers. Markers including Ter119, CD41,tion of DR6/DR6 ligand interaction might be a potential
CD220, CD45, and CD117 were used for bone marrow cell staining,strategy for the treatment of Th2-associated diseases,
while CD4, CD8, and CD3 were used as T cell markers for thymus
such as atopy and asthma. Thus, understanding the cell staining. CD4, CD8, Thy1.2, TCR
, and TCR were used as
DR6/DR6L signaling pathway may yield insights into the T cell markers; CD220, CD19, and IgM were used as B cell markers;
CD23 and IgD were used as B cell activation markers; NK1.1 wascontrol of diverse immune responses, including rheuma-
used as a nature killer cell marker; CD11c was used as a monocytetoid arthritis, graft-versus-host disease, and various
marker; Ly-6-G was used as a neutrophil marker; and CD69 andother autoimmune disorders.
CD25 were used as T and B cell activation markers. Both FITC-
and PE-conjugated anti-mouse antibodies were purchased from BD
PharMingen (San Diego, CA).Experimental Procedures
Generation of DR6-Deficient Mice Proliferation Assays
For T cell proliferation assays, purified T cells were stimulated forThe sequence of the murine DR6 cDNA was deposited in GenBank,
with an accession number AF322069. Using the sequence of DR6 48 hr or 72 hr and pulsed for the last 12 hr incubation with 1 Ci of
[3H]thymidine, and thymidine incorporation was quantitated usingcDNA as a probe, we isolated mouse genomic DNA clones corre-
sponding to the DR6 locus from mouse strain 129/Sv (FixII phage a scintillation counter. For IL-2 response assays, purified CD4 T
cells were stimulated with suboptimal concentration of anti-CD3/library, Stratagene Inc., La Jolla, CA). An 8.1 kb Stu-EcoRV genomic
DNA fragment corresponding to DR6 was identified. A targeting anti-CD28 (0.5 g/ml for both antibodies) for 12 hr. T cells were
then washed and stimulated with 50 ng/ml IL-2 for 48 hr, and thevector (pKO-DR6) was constructed in the vector pGT-N29 (New
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proliferation was measured by [3H]thymidine incorporation. Soluble ing, and anti-NF-ATc and anti-NF-ATp (BD PharMingen) were used
for supershift assays.DR6 treatment was similar to the above procedure, except that only
wild-type T cells or CD4 T cells and 0.2 g/ml anti-CD3 were used.
Soluble DR6 was obtained from R&D systems (Minneapolis, MN). Acknowledgments
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